CA
IRLA

CoreCap Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

CoreCap Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$335 – 2953
2024
Q3 		$335 Hold
2
– – ﹤0.01% 2413
2024
Q2 		$323 Hold
2
– – ﹤0.01% 1479
2024
Q1 		$457 Buy
+2
New +$497 ﹤0.01% 2345
2022
Q4 		$275 Buy
+2
New +$334 ﹤0.01% 2244
2022
Q3 		– Sell
-2
Closed -$1K – 1702
2022
Q2 		$1K Buy
+2
New +$1.41K ﹤0.01% 2039
2022
Q1 		– Sell
-2
Closed -$5K – 1702
2021
Q4 		$5K Buy
+2
New +$12.2K ﹤0.01% 1758

Other funds holding IRLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CoreCap Advisors's IRLA Position: Q4 2024 in Review

CoreCap Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2024, closing a stake of 2 shares — an estimated $335 sold.

CoreCap Advisors first reported a position in IRLA in Q4 2021 and held it in 6 quarters. The position peaked at $5K in Q4 2021. 33 funds tracked by Wall St. Rank hold IRLA as of Q4 2024.

  • CoreCap Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • CoreCap Advisors sold 2 IRulya Therapeutics Inc. Common Stock shares in Q4 2024, an estimated $335.
  • CoreCap Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2021 and held it in 6 quarters.
  • CoreCap Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $5K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2024.

Based on CoreCap Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.